%0 Journal Article
%T Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
%A Martorell A
%A Santos-Alarcón S
%A Sahuquillo-Torralba A
%A Rivera-Díaz R
%A Belinchón-Romero I
%A Ruiz-Genao D
%A Romero-Maté A
%A Ruiz-Villaverde R
%A Ferran-Farrés M
%A Gallardo-Hernández F
%A Almenara-Blasco M
%A Suarez-Perez JA
%A González-Cantero Á
%A Martínez-Lorenzo E
%A Fernández-Armenteros JM
%A Del Alcázar-Viladomiu E
%A García-Latasa J
%A Rocamora-Durant V
%A Ara-Martín M
%A Mateu-Puchades A
%A Llamas-Velasco M
%A Vilarrasa E
%A Velasco-Pastor M
%A De la Cueva P
%A Carrascosa JM
%A Magdaleno-Tapial J
%J Actas Dermosifiliogr
%V 0
%N 0
%D 2024 Mar 6
%M 38452889
暂无%R 10.1016/j.ad.2024.02.030
%X <B>OBJECTIVE: </B>Risankizumab - a humanized monoclonal antibody that targets the p19 subunit of IL-23 - has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking.<BR><B>OBJECTIVE: </B>To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice.<BR><B>METHODS: </B>This was a retrospective and multicenter study of consecutive psoriatic patients on risankizumab from April 2020 through November 2022. The primary endpoint was the number of patients who achieved a 100% improvement in their Psoriasis Area and Severity Index (PASI) (PASI100) on week 52.<BR><B>RESULTS: </B>A total of 510 patients, 198 (38.8%) women and 312 (61.2%) men were included in the study. The mean age was 51.7±14.4 years. A total of 227 (44.5%) study participants were obese (body mass index [BMI] >30kg/m2). The mean baseline PASI score was 11.4±7.2, and the rate of patients who achieved PASI100 on week 52, 67.0%. Throughout the study follow-up, 21%, 50.0%, 59.0%, and 66% of the patients achieved PASI100 on weeks 4, 16, 24, and 40, respectively. The number of patients who achieved a PASI ≤2 was greater in the group with a BMI ≤30kg/m2 on weeks 4 (P=.04), 16 (P=.001), and 52 (P=.002). A statistically significantly greater number of patients achieved PASI100 in the treatment-naïve group on weeks 16 and 52 (P=.001 each, respectively). On week 16 a significantly lower number of participants achieved PASI100 in the group with psoriatic arthropathy (P=.04). Among the overall study sample, 22 (4.3%) patients reported some type of adverse event and 20 (3.9%) discontinued treatment.<BR><B>CONCLUSIONS: </B>Risankizumab proved to be a safe and effective therapy for patients with moderate-to-severe psoriasis in the routine clinical practice.